替罗非班联合瑞舒伐他汀治疗急性脑梗死患者的临床价值探究OA

Objective To explore the clinical value of tirofiban combined with rosuvastatin in patients with acute cerebral infarction(ACI).Methods A total of 60 patients with initial ACI admitted to Kaifeng Central Hospital between January 2021 and January 2022 were selected and divided into control group and combined group according to randomized numerical table method,with 30 cases in each group.The patients in the control group were given conventional symptomatic treatment + oral rosuvastatin,and the combined group was given tirofiban on the basis of the control group,and the course of treatment for both groups was 1 month,the blood lipids[total cholesterol(TC),triacylglycerol(TG),low-density lipoprotein(LDL-C),high-density lipoprotein(HDL-C)],homocysteine(Hcy),and serum hypersensitive C reactive protein(hs-CRP)levels were compared;The coagulation function[fibrinogen(FIB),activated partial thromboplastin time(APTT),prothrombin time(PT)]of patients in the two groups were compared;The changes in neurological function of patients was evaluated by National Institutes of Health Stroke Scale(NIHSS)before and after treatment,and the adverse reactions were compared between the combined group and the control group.Results Before treatment,the levels of lipid indexes(TC,TG,LDL-C,HDL-C)measured before treatment were compared between the two groups of patients,and the difference was not statistically significant(P＞0.05);after treatment,the levels of lipids in the two groups were reduced compared with the pre-treatment levels,and the combined group was lower than that of the control group,and the difference was statistically significant(P＜0.05).Before treatment,the Hcy and hs-CRP levels of the two groups were compared,and the difference was not statistically significant(P＞0.05);after 1 month of treatment,the Hcy and hs-CRP levels of the two groups were reduced compared with those of the same group before treatment,and the combined group was lower than the control group,and the difference was statistically significant(P＜0.05).Before treatment,there was no statistically significant difference in FIB,APTT,and PT between the two groups(P＞0.05);After treatment,the FIB,APTT,and PT of both groups decreased,and the combined group was lower than the control group,with a statistically significant difference(P＜0.05).Before treatment,there was no statistically significant difference in NIHSS scores between the two groups(P＞0.05);After 1 month of treatment,the NIHSS scores of both groups decreased,and the combined group was lower than the control group,with a statistically significant difference(P＜0.05).The comparison of adverse reactions between the two groups showed no statistically significant difference(P＞0.05).The incidence of recurrent infarction in the combination group was lower than that in the control group,and the difference was statistically significant(P＜0.05).Conclusion The combination therapy of tirofiban and rosuvastatin can effectively reduce blood lipid levels and inhibit inflammatory reactions in patients with acute cerebral infarction.At the same time,it can improve brain blood flow and neurological function,and has a better therapeutic effect on ACI patients than rosuvastatin alone.